Wolf’s Finance World

TGen Drug Development and Rondaxe Enterprises have forged an alliance to help emerging companies speed new treatments to cancer patients.

Syracuse, N.Y.-based Rondaxe is a drug development consulting firm that helps emerging pharmaceutical and biotechnology firms navigate through all phases of the drug development and commercialization process.

Scottsdale-based TGen Drug Development, known as TD2, is a nonprofit subsidiary of the Phoenix-based Translational Genomics Research Institute. It specializes in guiding drug companies through clinical trials and moving drug candidates through the federal review process of the U.S. Food and Drug Administration.

The two organizations will work together to bridge a gap between chemistry and translational medicine. The goal is to expedite research discoveries through the regulatory process so patients can get treatments sooner.

For more: www.td2.org.

Source

Filed under: money by Wolf